New York, December 22, 2023 – PetVivo Holdings, Inc. (Nasdaq: PETV) has achieved a distribution milestone, reporting a total of 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year.
Spryng, the company’s signature product, helps to manage lameness, joint pain and osteoarthritis in horses and small animals. Earlier this month, the company announced the sale of Spryng to more than 600 veterinary clinics in 49 states.
John Lai, Chief Executive Officer of PetVivo Holdings, Inc., commented on the news, saying, “Achieving this distribution milestone involving Spryng is a testament to the unwavering support of the veterinarian community and their passion to help animals suffering from debilitating lameness related diseases, such as osteoarthritis.
“We’re grateful for all the veterinarians who have added Spryng to their toolbox of therapeutics and medical devices, and we’re thrilled that we are witnessing the positive impact Spryng has had in helping animals suffering from joint related afflictions.”
Veterinarian enthusiasm for Spryng continues to grow, with PetVivo reporting 2023 as being the “biggest year yet” for distribution, which has increased more than 60% from the previous year.
PetVivo says the momentum has been driven by the release of recent Spryng clinical study data, as well as numerous presentations and references at industry trade shows by reputable key opinion leaders in the equine and small animal veterinary community.
The company’s SPRYNG™ with OsteoCushion™ Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extracellular matrix microparticles. These microparticles have been found to adsorb onto the joint synovial lining of animals, integrating with the animal’s subsynovial tissue. This action promotes the restoration of proper joint mechanics, aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint-related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians.
PRISM Analysis: PetVivo (Nasdaq: $PETV) Holdings Achieves Distribution Milestone; Shares Soar 40%https://t.co/5EFCpApoLY#stockstowatch #StocksInNews #investors #PrismMarketView #PrismMediaWire #PrismDigitalMedia— PrismMarketView (@PrismMarketView) December 22, 2023
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
PRISM MarketView does not provide investment advice.